Claims

1. Use of a compound, or a pharmaceutically acceptable salt thereof:

in the manufacture of a medicament for the treatment, inhibition of progression, or prevention of cardiovascular calcification, in a subject in need thereof, wherein (a) the compound is myo-inositol hexaphosphate (b) the compound in a form suitable for parenteral, topical, or enteral administration, and (c) the compound is administered to the human subject in a non-bolus prolonged release form in an effective dosage of 200 mg to 700 mg per administration and (d) the dosage is administered at least once per week.

2. Use according to claim 1, wherein the cardiovascular calcification is coronary artery calcification, aortic artery calcification, or aortic valve calcification.

3. The use according to any one of claims 1-2, wherein the myo-inositol hexaphosphate is in its hexasodium salt form.

4. Use of a pharmaceutical composition in the manufacture of a medicament for the treatment, inhibition of progression, or prevention of cardiovascular calcification in a human subject in need thereof comprising the use of the compound according to any one of claims 1-3 and pharmaceutically acceptable excipients and carriers.

5. The use according to any one of claims 1-3 or according to claim 4, wherein the subject is with kidney failure.

6. The use according to any one of claims 1-3 or according to claim 4, wherein the subject is on dialysis.

7. The use according to any one of claims 1-6, wherein the parenteral administration is intravenous, subcutaneous, intramuscular or by intravenous infusion.

8. The use according to claim 7, wherein the intravenous infusion is administered using a dialysis apparatus.

9. The use according to any one of claims 1-8, wherein the compound is administered to the human subject in a dosage of 250 mg to 650 mg per administration to the human subject.

10. The use according to claim 9, wherein compound is administered to the human subject in a dosage of 300 mg to 600 mg per administration to the human subject.

11. The use according claim 10, wherein compound is administered to the human subject in a dosage of 350 mg to 550 mg per administration to the human subject.

12. The use according to any one of claims 1-11, wherein the dosage is administered in single daily doses.

13. The use according to any one of claims 1-11, wherein the dosage is administered as multiple daily doses.

14. The use according to any one of claims 1-13, wherein the dosage is administered for at least one week.

15. The use according to any one of claims 1-14, wherein the dosage is administered for 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, or 52 weeks.

16. A combined preparation comprising (a) the compound according to any one of claims 1-3 or the pharmaceutical composition according to claim 4 and (b) at least one second active agent.